Services

We deploy scientific expertise spanning organic chemistry, molecular biology, and systems-level thinking to develop innovative solutions to your most challenging scientific problems. Clients come to us not just to understand the science — but to build technology with it.

A defining capability is our ability to work across the full integration of wetware, hardware, and software — designing and developing systems where biology, instrumentation, and computation have to work together. This cross-disciplinary fluency, from the chemistry of nucleic acid systems through enzymology, molecular biology, and cellular biology, is rare and allows us to see solutions that specialists in any single domain will miss.

Large companies often employ rigid processes that impede innovation. Early-stage startups may initially forgo such structures — but usually find the hard way that they need them as they scale. The challenge is building processes that are correctly-scoped: robust enough to work, lean enough not to kill momentum.

We bring a unique advantage here: deep familiarity with the Danaher Business System (DBS) — widely considered the gold standard for operational excellence in large biotech — combined with the experience of having adapted and distilled those frameworks for companies at every stage. We know what to keep, what to cut, and how to sequence it.

Engagements have included: innovation and research program frameworks; product development stage gate processes; product planning, strategy and management; cross-functional organization design; IVD ISO 13485 / 510(k) development strategies; market analysis; technology roadmap development; grant writing; and strategic partnerships.

We've been in the room at every startup stage — as a co-founder and CTO (Legomics), as a VP of Research and Innovation (Ultivue), and as a scientific advisor to numerous companies spinning out of the Church lab and Wyss Institute. We understand what startup teams actually need, and it's rarely what they initially ask for.

Early engagements typically center on scientific strategy, technology validation, and helping founders communicate their science credibly to investors and partners. As companies mature, the work shifts to building the operational and organizational infrastructure that makes growth sustainable — including R&D frameworks, technology roadmaps, and grant strategy to extend runway.

Not every company needs — or can afford — a full-time Chief Scientific Officer or VP of R&D. But every company at a critical inflection point needs someone in that seat who has actually done it before. Fractional leadership gives you senior scientific and technical executive capacity on a flexible basis, without the commitment or cost of a full-time hire.

With direct experience as Chief Scientist and Head of Genomics R&D at Beckman Coulter (Danaher), VP of Research and Innovation at Ultivue, and CTO at Legomics, we bring genuine executive operating experience across the full range of company stages — from early-stage startups building their first R&D function to established companies managing complex multi-product portfolios.

Fractional engagements are structured around your specific needs: setting and executing scientific strategy, building and leading R&D teams, representing the science to investors and the board, managing technology development programs, or serving as an interim executive during a leadership transition. We integrate as a true member of your leadership team — not a consultant on the outside looking in.

We provide independent scientific and technical due diligence for investment and M&A decisions. We go beyond surface-level science assessment to evaluate the full picture: is the core science sound, is the technology differentiated, what are the real technical risks, and does the team have the capability to execute?

Our diligence work is grounded in direct experience on both sides — as a Beckman Coulter/Danaher diligence team member for M&A, and as a scientific founder and executive who has been on the receiving end of that process. We know what questions matter and where the bodies are buried.

We bring extensive hands-on experience in technology scouting, in-licensing, and out-licensing across the full spectrum of sources — academic technology transfer offices, non-profit organizations, early-stage companies, and large multinationals.

On the out-licensing side, we specialize in complex deal structures and technology valuation. Whether the deal is equity-based, royalty-based, hybrid, or involves market, use, or regional exclusivity, we've structured it — and we know how to model the value on both sides of the table.